140 related articles for article (PubMed ID: 8288088)
21. [Parkinsonism in a patient receiving interferon alpha therapy for chronic hepatitis C].
Mizoi Y; Kaneko H; Oharazawa A; Kuroiwa H
Rinsho Shinkeigaku; 1997 Jan; 37(1):54-6. PubMed ID: 9146076
[TBL] [Abstract][Full Text] [Related]
22. [Therapy of chronic hepatitis B, C and D with alpha-interferon].
Niederau C
Fortschr Med; 1993 Feb; 111(6):35-7. PubMed ID: 8462911
[No Abstract] [Full Text] [Related]
23. Hepatitis C virus and oral lichen planus/lichenoid reactions: lack of evidence for an association.
Roy KM; Dickson EM; Staines KS; Bagg J
Clin Lab; 2000; 46(5-6):251-4. PubMed ID: 10853232
[TBL] [Abstract][Full Text] [Related]
24. [Is the treatment of chronic viral hepatitis C with interferon-alpha effective?].
Beker S; Pujol FH; Beker B
G E N; 1995; 49(2):165-9. PubMed ID: 8566691
[No Abstract] [Full Text] [Related]
25. Comparison of treatment with two different doses of leukocyte interferon alpha in patients with chronic hepatitis C.
Laghi V; Toccaceli F; Rosati S; Monini A; Grimaldi M; Foglianti G; Canova N; Palazzini E
Hepatogastroenterology; 1997; 44(16):1182-6. PubMed ID: 9261621
[TBL] [Abstract][Full Text] [Related]
26. Canities and vitiligo complicating interferon therapy for hepatitis C.
Bernstein D; Reddy KR; Jeffers L; Schiff E
Am J Gastroenterol; 1995 Jul; 90(7):1176-7. PubMed ID: 7611226
[No Abstract] [Full Text] [Related]
27. Immune thrombocytopenia after alpha-interferon therapy in a patient with chronic hepatitis C.
López Morante AJ; Sáez-Royuela F; Casanova Valero F; Yuguero del Moral L; Martín Lorente JL; Ojeda Giménez C
Am J Gastroenterol; 1992 Jun; 87(6):809-10. PubMed ID: 1590332
[No Abstract] [Full Text] [Related]
28. [Multiple extrahepatic manifestations in a patient with chronic hepatitis C treated with interferon-alfa].
Napoli N; Tortorella C; Deramo MT; Antonaci A; Parisi CV; Antonaci S
Recenti Prog Med; 2004 Nov; 95(11):525-8. PubMed ID: 15598090
[TBL] [Abstract][Full Text] [Related]
29. Lichen planus and chronic hepatitis C: exacerbation of the lichen under interferon-alpha-2a therapy.
Areias J; Velho GC; Cerqueira R; Barbêdo C; Amaral B; Sanches M; Massa A; Saraiva AM
Eur J Gastroenterol Hepatol; 1996 Aug; 8(8):825-8. PubMed ID: 8864684
[TBL] [Abstract][Full Text] [Related]
30. Oral erosive lichen planus with epidermolytic hyperkeratosis during interferon alfa-2b therapy for chronic hepatitis C virus infection.
Schlesinger TE; Camisa C; Gay JD; Bergfeld WF
J Am Acad Dermatol; 1997 Jun; 36(6 Pt 1):1023-5. PubMed ID: 9204077
[No Abstract] [Full Text] [Related]
31. [When should the treatment with interferon alpha be discontinued in chronic hepatitis C?].
Castilla Cortázar A
Med Clin (Barc); 1993 Dec; 101(20):774-6. PubMed ID: 8114538
[No Abstract] [Full Text] [Related]
32. [Should hepatitis C be treated? Which biological tests are useful before deciding or refuting a treatment with interferon-alpha in patients with chronic hepatitis C?].
Pawlotsky JM
Gastroenterol Clin Biol; 1997; 21(1 Pt 2):S41-50. PubMed ID: 9161513
[No Abstract] [Full Text] [Related]
33. Membranoproliferative glomerulonephritis and hepatitis C: effects of interferon-alpha therapy on clinical outcome and histological pattern.
Morosetti M; Sciarra G; Meloni C; Palmieri G; Palombo G; Taccone Gallucci M; Casciani CU
Nephrol Dial Transplant; 1996 Mar; 11(3):532-4. PubMed ID: 8671827
[No Abstract] [Full Text] [Related]
34. Lichenoid Dermatitis From Interferon alpha-2a in a Patient With Metastatic Renal Cell Carcinoma and Seronegative HCV.
Bush AE; Hymes SR; Silapunt S
J Drugs Dermatol; 2017 Jul; 16(7):714-716. PubMed ID: 28697228
[TBL] [Abstract][Full Text] [Related]
35. [The treatment of chronic viral hepatitis B/D and acute and chronic viral hepatitis C. The consensus of the German Society for Digestive and Metabolic Diseases].
Hopf U; Niederau C; Kleber G; Fleig WE
Z Gastroenterol; 1997 Nov; 35(11):971-86. PubMed ID: 9490556
[No Abstract] [Full Text] [Related]
36. [Appearance of antiphospholipid antibodies in patients with hepatitis C treated with interferon-alpha].
Doutre MS; Baquey A; Bernard P; Couzigou P; Bernard N; Lacoste D; Morlat P
Ann Med Interne (Paris); 1997; 148(1):99-100. PubMed ID: 9137700
[No Abstract] [Full Text] [Related]
37. Serum hyaluronate predicts response to interferon-alpha therapy in patients with chronic hepatitis C.
Ueno T; Inuzuka S; Sata M; Koh H; Tamaki S; Kin M; Sugawara H; Sakata R; Torimura T; Tanikawa K
Hepatogastroenterology; 1995; 42(5):522-7. PubMed ID: 8751209
[TBL] [Abstract][Full Text] [Related]
38. [Association of chronic hepatitis C and lichen planus--in two patients].
Podányi B; Lengyel G; Kiss A; Szakonyi J; Schaff Z; Fehér J
Orv Hetil; 2006 Mar; 147(12):547-50. PubMed ID: 16696378
[TBL] [Abstract][Full Text] [Related]
39. Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study.
Bargiggia S; Thorburn D; Anderloni A; Ardizzone S; Giorgi A; Bianchi Porro G; Parente F
Aliment Pharmacol Ther; 2005 Aug; 22(3):209-15. PubMed ID: 16091058
[TBL] [Abstract][Full Text] [Related]
40. [Interferon-alpha in chronic hepatitis C].
Swobodnik W
Dtsch Med Wochenschr; 1995 Aug; 120(34-35):1186. PubMed ID: 7656857
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
